Navigation Links
Key player found for a cancer typical in Down syndrome
Date:3/1/2010

Boston, Mass. Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets. Now, researchers at Children's Hospital Boston have found a gene regulator they believe to be a key player in DS-AMKL, advancing understanding of how the disease develops and how to treat it.

The study findings, published in the March 1 issue of Genes and Development, may also help in understanding other forms of leukemia, the researchers say.

The gene regulator, miR-125b-2, belongs to a class of molecules known as microRNAs, which silence gene expression by halting the manufacturing of different proteins. While microRNAs are important to normal cell function, unusual amounts of them can lead to disease. "DS-AMKL has a very strong genetic basis," says senior investigator Stuart Orkin, MD, of the Division of Hematology/Oncology at Children's. "However, there aren't that many cancers in which a particular microRNA can be pointed to as contributing."

Because children with Down syndrome have three copies of chromosome 21 rather than the usual two copies, the researchers focused on the five microRNAs produced by this chromosome, and zeroed in on miR-125b-2.

"In human primary DS-AMKL cells, this microRNA is quite dramatically over-expressed," says Zhe Li, PhD, of Children's Division of Hematology/Oncology and first author of the paper. "We then went back and studied how over-expression or downregulation of this microRNA affects the phenotype of leukemia cells."

DS-AMKL is always associated with mutations in the gene GATA1, which helps make and regulate red blood cells and megakaryocytes (the cells that produce platelets). The increased incidence of this leukemia in children with Down syndrome convinced the researchers that a GATA1 mutation may be joining forces with some genetic factor on chromosome 21 specifically, miR-125b-2.

"GATA1 is always mutated, while miR-125b-2 is always over-expressed in leukemic cells," Li says. "Do they cooperate?"

The researchers experimented on genetically engineered mice that specifically expressed the mutant version of GATA1. Cells were taken from the fetal livers of these mice and induced into becoming blood progenitor cells that either made both red blood cells and megakaryocytes (MEP) or only made megakaryocytes (MP). The researchers then used a virus to over-express miR-125b-2 in these cells and compared them to MEP and MP cells without a GATA1 mutation.

Although over-expression of miR-125b-2 caused increased growth and replication of MEP and MP cells with or without the GATA1 mutation, the growth was further enhanced in the presence of the GATA1 mutation. But once the researchers down-regulated this microRNA in DS-AMKL leukemic cells, which have both GATA1 mutation and miR-125b-2 over-expression, the aberrant growth stopped. These observations support the notion that GATA1 mutation and over-expression of miR-125b-2 are both needed for DS-AMKL to develop.

Further tests on these cells suggested that over-expression of miR-125b-2 spurs the leukemia by silencing two genes: one for tumor-suppression, and another for producing other regulatory microRNAs.

Genetic analyses of leukemia cells taken from DS-AMKL patients confirmed the results seen in the mouse models. The next step is for researchers to model DS-AMKL in vivo, using animal cells and, eventually, fetal cells.

Studying leukemia in Down syndrome patients may help scientists understand and treat other forms of the cancer, says Orkin. Past research has shown that other genes on chromosome 21 may be involved in other types of leukemia. "Learning more about the genetics of leukemia will then lead to some thoughts about other ways to interfere with the growth of the cells," Orkin says.


'/>"/>

Contact: Rob Graham
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related biology news :

1. Little-known protein found to be key player
2. New study finds lowfat chocolate milk is effective post-exercise recovery aid for soccer players
3. New estrogen receptor found to be key player in tamoxifen resistance
4. Frost & Sullivan Recognizes Precise Biometrics as a Key Player in the Non-AFIS Fingerprint Market
5. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
6. Black carbon pollution emerges as major player in global warming
7. Scientists discover a new player in innate immune response
8. Rockefeller Foundation supports expansion, training of e-health work force in developing world
9. Lymphoma Research Foundation announces publication of Mantle Cell report
10. Anorexics found to have excess fat-- in their bone marrow
11. Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... , ... February 21, 2017 , ... ... transformative design and manufacturing solutions for original equipment manufacturers (OEMs) , today announced ... marks Creation Technologies’ third consecutive year winning in its category of electronics manufacturing ...
(Date:2/21/2017)... 2017 Scientists From Two Companies ... Plastic Industry  ... STEER, creator of advanced materials platform ... fields of plastics, pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, ... science & technology company, on creating co-rotating twin screw ...
(Date:2/20/2017)... BIOA ) announced today that Jean-Francois Huc ... COO, has been named President, effective immediately.  In ... overseen the construction, start-up and operation of the manufacturing plant in ... JV.  Fabrice has also been extensively involved in the negotiations with ... ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer ... “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization and decision support ... accessed through Inspirata’s diagnostic cockpit and is downloadable as an app for any ...
Breaking Biology Technology: